Aquestive Therapeutics, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Aquestive Therapeutics, Inc. (AQST) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $157.00 thousand as of 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2024-05-07
- 2024-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $157.00K.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $157.00K.
- 2023-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $156.00K.
- 2023-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $156.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2024-03-31 | $157.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $157.00K 10-K · filed 2024-03-05 |
| 2023-09-30 | $156.00K 10-Q · filed 2023-11-06 |
| 2023-06-30 | $156.00K 10-Q · filed 2023-08-07 |
| 2022-12-31 | $156.00K 10-K · filed 2023-03-31 |
| 2021-12-31 | $51.00K 10-K · filed 2022-03-08 |
| 2021-09-30 | $50.00K 10-Q · filed 2021-11-02 |
| 2021-06-30 | $50.00K 10-Q · filed 2021-08-03 |
| 2021-03-31 | $50.00K 10-Q · filed 2021-05-04 |
| 2020-12-31 | $51.00K 10-K · filed 2021-03-09 |
| 2020-09-30 | $50.00K 10-Q · filed 2020-11-04 |
| 2020-06-30 | $50.00K 10-Q · filed 2020-08-04 |
| 2020-03-31 | $50.00K 10-Q · filed 2020-05-05 |
| 2019-12-31 | $50.00K 10-K · filed 2020-03-11 |
| 2018-12-31 | $50.00K 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |